ArticleJournal of lipid research2026
Macrophage source influences peritoneal persistence and immune cell dynamics in assays of reverse cholesterol transport.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Assays to measure macrophage-to-feces reverse cholesterol transport (RCT) in mouse models are well-established, yet the immunologic consequences of injecting allogeneic versus syngeneic macrophages remain undefined in the context of this assay. In this study, we compared primary bone marrow-derived macrophages (BMDMs) and reticulosarcoma-derived J774 macrophages as cholesterol-loaded donor cells in a well-established in vivo RCT assay to determine whether macrophage origin influences host immune activation and cholesterol flux. Following intraperitoneal injection, J774 macrophages exhibited markedly reduced peritoneal persistence relative to BMDMs, with <1% of cells detectable at 24 or 48 h postinjection, compared to sustained retention of the BMDMs. This was accompanied by distinct immune activation profiles where J774 macrophages induced prolonged innate immune activation, whereas BMDMs elicited coordinated and transient responses involving early B cell activation that resolved by 48 h. Despite these differences in cellular persistence and immune response, RCT outcomes were comparable between groups under the conditions tested, with no major differences observed in hepatic uptake or fecal excretion of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.